Kronos Bio engages in research and development of therapies that modulate historically recalcitrant cancer targets. It develops chemical modulators of transcription factors and other recalcitrant targets by combining small molecule microarrays in oncology treatment. The Company develops MYC family of transcription factors that master regulators of cell proliferation and differentiation by developing a series of compounds which acts through a novel mechanism to suppress MYC-driven transcription.